Apogee Therapeutics (NASDAQ:APGE) Hits New 52-Week High at $38.34

Apogee Therapeutics is a biopharmaceutical company that specializes in developing and commercializing novel therapies for rare genetic disorders. The company's lead product candidate is APG-103, an oral therapy for the treatment of phenylketonuria (PKU), a rare genetic disorder that affects the metabolism of amino acids.

On August 24, 2022, Apogee Therapeutics announced that its stock price had reached a new 52-week high of $38.34 on the NASDAQ Global Select Market. This represents an increase of over 160% from the company's 52-week low of $14.79, which was reached on March 15, 2022.

The stock price increase can be attributed to several factors, including positive news about APG-103's clinical trial results and regulatory progress, as well as increasing investor interest in the rare disease market. In addition, Apogee Therapeutics has recently announced plans to expand its operations and develop new therapies for other rare genetic disorders.

Overall, the stock price increase reflects investors' confidence in the company's ability to successfully bring APG-103 to market and generate revenue from its commercialization.